The Wall Street Journal editorial board continued on Tuesday to express its rage at the Trump FDA for blocking experimental treatments. Specifically, the board took aim at efforts by regulators to stifle new therapies for late-stage melanoma and Duchenne muscular dystrophy. "The FDA under acting Commissioner Kyle Diamantas in recent months appeared to be turning around," the board wrote. But now, FDA staff have once again advanced the same arguments that Makari and Prasad's deputies used to block Replimune's cancer therapy and Capricor Therapeutics' cell therapy to treat Duchenne. If only biopsies had such miraculous effects," the board wrote.